{"id":180941,"date":"2026-02-16T04:54:11","date_gmt":"2026-02-16T09:54:11","guid":{"rendered":"https:\/\/alphastreet.com\/india\/?p=180941"},"modified":"2026-02-16T04:54:11","modified_gmt":"2026-02-16T09:54:11","slug":"sanjivani-parenteral-q3-profit-jumps-38-on-export-led-growth","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/sanjivani-parenteral-q3-profit-jumps-38-on-export-led-growth\/","title":{"rendered":"Sanjivani Parenteral Q3 Profit Jumps 38% on Export-Led Growth"},"content":{"rendered":"\n
Sanjivani Parenteral Limited (BSE: 531569), a manufacturer of parenteral and oral solid dosage formulations across therapeutic areas including CNS, cardiovascular, anti-diabetics, anti-infectives and gastroenterology, reported a 37.8% year-on-year rise in standalone net profit for the third quarter ended December 31, 2025, driven by strong export demand and improved operating leverage in its injectables business.<\/p>\n\n\n\n
The company operates manufacturing plants in Navi Mumbai and Dehradun, along with an IV facility in Pune and a European presence in Prague through Alevia Healthcare. It exports to 25 countries, with nearly 75% of revenue derived from international markets.<\/p>\n\n\n\n
As of Dec. 31, 2025, Sanjivani Parenteral Limited had a market capitalisation of INR 2.8 billion, with its shares trading at INR 231 on the BSE. The stock has moved between INR 182 and INR 383 over the past 52 weeks. Promoters hold a 31% stake, while retail investors account for 37%. Institutions own 6%, high net-worth individuals 19%, and corporate bodies 8%<\/p>\n\n\n\n
Revenue from operations rose 20.3% to INR 208.6 million in Q3 FY26.
EBITDA increased 35.7% to INR 38.8 million, with margin expanding 216 basis points to 18.4%.<\/li><\/ul>\n
\n
Profit after tax stood at INR 26.2 million.<\/li>\n<\/ul>\n<\/li>\n\n\n\n
For the nine months ended December 31, revenue grew 4.5% year-on-year to INR 542.5 million.\n
\n
Net profit rose 1.3% to INR 59.9 million, while EBITDA increased 5.3% to INR 89.8 million, with margins steady at 16.4%.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<\/figure>\n\n\n\n
Segment and Product Mix<\/strong><\/h2>\n\n\n\n
\n
Injectables contributed 55.9% of Q3 FY26 revenue, tablets accounted for 41.4%, and nutraceuticals made up 2.7%.<\/li>\n\n\n\n
Segment-wise, injectables remain the primary growth driver, supported by expanded production capabilities and regulatory compliance certifications including WHO-GMP.<\/li>\n<\/ul>\n\n\n\n
Geographical Revenue Mix<\/strong><\/h2>\n\n\n\n
\n
Exports accounted for 76.9% of Q3 revenue and 77.2% of nine-month revenue.<\/li>\n\n\n\n
Regionally, Middle East & Africa contributed 46.7% in Q3 FY26, Latin America 28.8%, India & subcontinent 23.1%, and CIS countries 1.3%.<\/li>\n<\/ul>\n\n\n\n
Joint venture with Alevia Healthcare S.R.O., Prague (May 2023), with commercial batches underway.<\/li>\n\n\n\n
Joint venture with Hindustan Antibiotics Ltd (August 2023).<\/li>\n\n\n\n
Expansion of product portfolio beyond 100 products.<\/li>\n\n\n\n
Strengthening of CDMO partnerships across injectables and oral segments.<\/li>\n<\/ul>\n\n\n\n
Management has outlined long-term growth drivers including product expansion, new geographies, therapeutic diversification and strategic collaborations.<\/p>\n\n\n\n
Industry Outlook<\/strong><\/h2>\n\n\n\n
According to IQVIA data, global medicine usage is projected to reach 3,778 billion defined daily doses by 2028, with India and China among the fastest-growing markets. Rising global demand for generics supports export-oriented manufacturers.<\/p>\n\n\n\n
Key Takeaway<\/strong><\/h2>\n\n\n\n
Strong Q3 margin expansion and export-led revenue growth signal improving operating efficiency. While nine-month growth remains moderate, the company\u2019s injectables focus, global footprint and strategic partnerships position it to benefit from rising international generic demand.<\/p>\n","protected":false},"excerpt":{"rendered":"
Sanjivani Parenteral Limited (BSE: 531569), a manufacturer of parenteral and oral solid dosage formulations across therapeutic areas including CNS, cardiovascular, anti-diabetics, anti-infectives and gastroenterology, reported a 37.8% year-on-year rise in standalone net profit for the third quarter ended December 31, 2025, driven by strong export demand and improved operating leverage in its injectables business. The […]<\/p>\n","protected":false},"author":2378,"featured_media":125269,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[5,1941,392,5747],"tags":[13198,16584,16585],"class_list":["post-180941","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest","category-stock-analysis","category-earnings","category-healthcare-stocks","tag-injectables","tag-pharmaceuticals-drugs","tag-sanjivin"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":167748,"url":"https:\/\/alphastreet.com\/india\/gland-pharma-ltd-q3fy25-7-rise-in-profits\/","url_meta":{"origin":180941,"position":0},"title":"Gland Pharma Ltd Q3FY25; 7% rise in Profits","author":"Divyansh_Kasana","date":"April 4, 2025","format":false,"excerpt":"Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/04\/L-3.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/04\/L-3.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/04\/L-3.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/04\/L-3.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/04\/L-3.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/04\/L-3.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":176434,"url":"https:\/\/alphastreet.com\/india\/sanjivani-paranteral-ltd-sanjivin-q2-2025-earnings-call-transcript\/","url_meta":{"origin":180941,"position":1},"title":"Sanjivani Paranteral Ltd (SANJIVIN) Q2 2025 Earnings Call Transcript","author":"News desk","date":"January 22, 2026","format":false,"excerpt":"Sanjivani Paranteral Ltd (NSE: SANJIVIN) Q2 2025 Earnings Call dated Oct. 29, 2024 Corporate Participants: Jill Chandrani \u2014 Senior Associate Analyst Srivardhan Khemka \u2014 Executive Director Pritesh Jain \u2014 Chief Financial Officer Ashwani Khemka \u2014 Chairman and Managing Director Analysts: Ishita Jain \u2014 Analyst Priya Sharma \u2014 Analyst Neeraj \u2014\u2026","rel":"","context":"In "Earnings Call Transcripts"","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":135146,"url":"https:\/\/alphastreet.com\/india\/infographic-gland-pharma-ltd-nse-gland-q2-results-total-revenue-%e2%82%b9-1110-28-million-up-19-7-qoq\/","url_meta":{"origin":180941,"position":2},"title":"Infographic : Gland Pharma Ltd (NSE : GLAND) Q2 Results; Total Revenue = \u20b9 1110.28 million ( UP 19.7 % QoQ)","author":"Divyansh_Kasana","date":"October 26, 2022","format":false,"excerpt":"Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing generic injectables manufacturing companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia,\u2026","rel":"","context":"In "Analysis"","block_context":{"text":"Analysis","link":"https:\/\/alphastreet.com\/india\/category\/stock-analysis\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/jubilant-pharma.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/jubilant-pharma.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/jubilant-pharma.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/jubilant-pharma.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/jubilant-pharma.jpg?resize=1050%2C600&ssl=1 3x"},"classes":[]},{"id":169143,"url":"https:\/\/alphastreet.com\/india\/gland-pharma-ltd-q4fy25-3-fall-in-profits\/","url_meta":{"origin":180941,"position":3},"title":"Gland Pharma Ltd Q4FY25; 3% fall in Profits","author":"Divyansh_Kasana","date":"July 15, 2025","format":false,"excerpt":"Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/U-9.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/U-9.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/U-9.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/U-9.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/U-9.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/U-9.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":151507,"url":"https:\/\/alphastreet.com\/india\/gland-pharma-ltd-q1fy24-18-fall-in-profits\/","url_meta":{"origin":180941,"position":4},"title":"Gland Pharma Ltd Q1FY24; 18% fall in Profits","author":"Hardik Bhandare","date":"August 7, 2023","format":false,"excerpt":"Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-278.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-278.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-278.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-278.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-278.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-278.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":163825,"url":"https:\/\/alphastreet.com\/india\/gland-pharma-ltd-q1fy25-26-fall-in-profits\/","url_meta":{"origin":180941,"position":5},"title":"Gland Pharma Ltd Q1FY25; 26% fall in Profits","author":"Divyansh_Kasana","date":"August 14, 2024","format":false,"excerpt":"Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-92.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-92.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-92.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-92.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-92.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/08\/image-92.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/180941","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/2378"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=180941"}],"version-history":[{"count":3,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/180941\/revisions"}],"predecessor-version":[{"id":180947,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/180941\/revisions\/180947"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125269"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=180941"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=180941"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=180941"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"\"](\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/Untitled-design-2-1024x576.png\")
<\/figure>\n\n\n\n